Drug Shortages and Their Impact on Cardio-Oncology Care

In the dynamic world of healthcare, drug shortages pose a significant challenge, particularly within the specialised sector of cardio-oncology. This broadcast delves into the pressing issue of drug shortages and their profound implications on patient care at the intersection of cardiovascular disease and cancer. 

This broadcast offers a platform for knowledge exchange, ensuring that healthcare professionals are well-equipped to navigate challenges, advocate for change and provide the best possible care for their cardio-oncology patients.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits. 

This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement

This is an independent activity run by the International cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance, Eli Lilly and Roche through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.